Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 3/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | BECN1 | Q14457 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180230 | 0.91 | CYP17A1 (0.46) | PSMB8CYP17A1BRD9BRD4CHRM1 | |
| SCHEMBL13666020 | 0.85 | CYP17A1 (0.41) | PSMB8CYP17A1BRD9BRD4CHRM1 | |
| SCHEMBL1179360 | 0.83 | BRD9 (0.45) | PSMB8CYP17A1BRD9BRD4P2RY14 | |
| SCHEMBL1179762 | 0.80 | BRD9 (0.44) | PSMB8CYP17A1BRD9BRD4P2RY14 | |
| SCHEMBL1180737 | 0.77 | BRD9 (0.43) | PSMB8CYP17A1BRD9BRD4CHRM1 | |
| SCHEMBL1180784 | 0.75 | CYP1A2 (0.34) | BRD9BRD4 | |
| SCHEMBL1180082 | 0.74 | DDX3X (0.50) | MAP4K4 | |
| SCHEMBL1180679 | 0.74 | DDX3X (0.46) | MAP4K4 | |
| SCHEMBL1179959 | 0.72 | CYP17A1 (0.48) | PSMB8CYP17A1BRD9BRD4P2RY14 | |
| SCHEMBL12872702 | 0.71 | BRD4 (0.45) | PSMB8CYP17A1BRD9BRD4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | PSMB8 4481/4885CYP17A1 1538/4885BRD9 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.